"“The efficacy of Prurisol was tested in vivo using a human psoriatic skin xenograft model in SCID mice. Endpoints included: appearance, histology, Psoriasis susceptibility-related RNA Gene Induced by Stress [PRINS, Sonkoly, et al. 2005], and blood levels of IL-20, CD4+ T cells, and CD8+ T cells. Activity was compared to standard therapies of methotrexate (MTX), a folate antagonist which inhibits proliferation of psoriatic cells and efalizumab, an immunosuppressive, recombinant humanized anti-CD11a monoclonal antibody that blocks the activation, adhesion, and trafficking of T-cells used in the treatment of psoriasis.”
“ Mice treated with Prurisol showed no reoccurrence of psoriatic lesions during the experiment, whereas animals treated with MTX showed a median reoccurrence of lesions by the 57th day.”
Cellceutix has previously disclosed images of mice treated with Prurisol™ demonstrating its effectiveness as compared to methotrexate, a standard care treatment for psoriasis today.
News 
Market Data 
Discover 
AI
